Dr. Gary D. Berman, M.D.
Allergy & Immunology (Clinical & Laboratory Immunology (Allergy & Immunology) Physician)
- Medicare participating
At a glance
- Medical school
- Mayo Medical School (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 112
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Mayo Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical & Laboratory Immunology (Allergy & Immunology) Physician primary
MN license 37947
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Ear Nose and Throat Specialty Care of Minnesota PA (46 clinicians)
- Allergy and Asthma Specialists, PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 112
- Services billed
- 1,745
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 750 | 20 |
| Professional service for preparation and provision of 1 or more antigens | 630 | 13 |
| Test for allergy using allergenic extract injected into skin | 238 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 193 | 104 |
| Professional service for multiple injections of allergen | 177 | 16 |
| Test to measure expiratory airflow and volume | 99 | 60 |
| Injection of drug or substance under skin or into muscle | 36 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Minneapolis, MN | 132 |
| Ipratropium Bromide Other prescribers in Minneapolis, MN | 119 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Minneapolis, MN | 111 |
| Fluticasone Propionate Other prescribers in Minneapolis, MN | 98 |
| Montelukast Sodium Other prescribers in Minneapolis, MN | 88 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Minneapolis, MN | 87 |
| Levocetirizine Dihydrochloride Other prescribers in Minneapolis, MN | 80 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Minneapolis, MN | 72 |
| Azelastine Hcl Other prescribers in Minneapolis, MN | 56 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Minneapolis, MN | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $88.22 in total to this clinician.
| AbbVie Inc. | $30.01 |
|---|---|
| Hologic Sales and Service, LLC | $29.48 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.56 |
| Pfizer Inc. | $14.17 |
| Food and Beverage | $88.22 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 20 industry-funded studies in 2025, from 8 companies. The companies reported $2,124,647 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - IMMULITE Peanut panel study
Siemens Medical Solutions USA, Inc. - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT04649151 - A randomized, double-blind, parallel group, multi-center study to eval
GlaxoSmithKline, LLC. - A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
ModernaTX, Inc. · Completed · NCT05975099 - Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. · Completed · NCT05827978 - Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06572228
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.